Search

Your search keyword '"VIANELLI N"' showing total 8 results
Start Over Author "VIANELLI N" Publication Year Range Last 3 years
8 results on '"VIANELLI N"'

3. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME

Author

Palandri, F., primary, Bartoletti, D., additional, Breccia, M., additional, Auteri, G., additional, Elli, E. M., additional, Trawinska, M. M., additional, Polverelli, N., additional, Tiribelli, M., additional, Benevolo, G., additional, Iurlo, A., additional, Tieghi, A., additional, Heidel, F. H., additional, Caocci, G., additional, Beggiato, E., additional, Binotto, G., additional, Cavazzini, F., additional, Miglino, M., additional, Bosi, C., additional, Crugnola, M., additional, Bocchia, M., additional, Martino, B., additional, Pugliese, N., additional, Romagnoli, A. D., additional, Mazzoni, C., additional, Scaffidi, L., additional, Isidori, A., additional, Cattaneo, D., additional, Krampera, M., additional, Pane, F., additional, Cilloni, D., additional, Semenzato, G., additional, Lemoli, R. M., additional, Cuneo, A., additional, Abruzzese, E., additional, Vianelli, N., additional, Cavo, M., additional, Bonifacio, M., additional, and Palumbo, G. A., additional

Published
2022
Full Text
View/download PDF

4. S292: SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL

Author

Cooper, N., primary, Ghanima, W., additional, Vianelli, N., additional, Valcárcel, D., additional, Yavaşoğlu, I., additional, Melikyan, A., additional, Yañez Ruiz, E., additional, Haenig, J., additional, Lee, J., additional, Maier, J., additional, Zolkin, N., additional, and Zaja, F., additional

Published
2022
Full Text
View/download PDF

5. P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS

Author

Gill, H., primary, Yacoub, A., additional, Pettit, K., additional, Bradley, T., additional, Gerds, A., additional, Tatarczuch, M., additional, Shortt, J., additional, Curtin, N., additional, Rossetti, J., additional, Burbury, K., additional, Mead, A., additional, Göthert, J., additional, Koschmieder, S., additional, Jones, A., additional, Peppe, J., additional, Dias, J., additional, Natsoulis, G., additional, McClure, T., additional, Kleppe, M., additional, Hong, W.-J., additional, Stevenson, W., additional, Ewing, J., additional, Chacko, J., additional, Rumi, E., additional, Halpern, A., additional, Palandri, F., additional, Vianelli, N., additional, Passamonti, F., additional, Mesa, R., additional, Marchetti, M., additional, Harrison, C., additional, Vannucchi, A., additional, Watts, J., additional, Ross, D., additional, Talpaz, M., additional, and Rienhoff, H., additional

Published
2022
Full Text
View/download PDF

6. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB

Author

Palandri, F., primary, Bartoletti, D., additional, Elli, E. M., additional, Auteri, G., additional, Bonifacio, M., additional, Benevolo, G., additional, Heidel, F., additional, Trawinska, M. M., additional, Rossi, E., additional, Bosi, C., additional, Tieghi, A., additional, Tiribelli, M., additional, Iurlo, A., additional, Polverelli, N., additional, Caocci, G., additional, Binotto, G., additional, Cavazzini, F., additional, Beggiato, E., additional, Cilloni, D., additional, Tatarelli, C., additional, Mendicino, F., additional, Miglino, M., additional, Bocchia, M., additional, Crugnola, M., additional, Mazzoni, C., additional, Romagnoli, A. D., additional, Rindone, G., additional, Ceglie, S., additional, D’Addio, A., additional, Santoni, E., additional, Cattaneo, D., additional, Lemoli, R. M., additional, Krampera, M., additional, Cuneo, A., additional, Semenzato, G., additional, Latagliata, R., additional, Abruzzese, E., additional, Vianelli, N., additional, Cavo, M., additional, Andriani, A., additional, De Stefano, V., additional, Palumbo, G., additional, and Breccia, M., additional

Published
2022
Full Text
View/download PDF

7. P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

Author

Palandri, F., primary, Ross, D. M., additional, Cochrane, T., additional, Tate, C., additional, Lane, S. W., additional, Larsen, S. R., additional, Gerds, A. T., additional, Halpern, A. B., additional, Shortt, J., additional, Rossetti, J. M., additional, Pettit, K. M., additional, Liang, J., additional, Mead, A., additional, Marchetti, M., additional, Vannucchi, A., additional, Wilson, A., additional, Göthert, J. R., additional, Hanna, M., additional, Jones, A., additional, Peppe, J., additional, Natsoulis, G., additional, McClure, T., additional, Hong, W.-J., additional, Stevenson, W. S., additional, Harrison, C. N., additional, Talpaz, M., additional, Vianelli, N., additional, and Rienhoff, H. Y., additional

Published
2022
Full Text
View/download PDF

8. An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera

Author

Monica Barone, Martina Barone, Francesca Ricci, Giuseppe Auteri, Giulia Corradi, Francesco Fabbri, Valentina Papa, Erika Bandini, Giovanna Cenacchi, Pier Luigi Tazzari, Nicola Vianelli, Silvia Turroni, Michele Cavo, Francesca Palandri, Marco Candela, Lucia Catani, Barone M., Ricci F., Auteri G., Corradi G., Fabbri F., Papa V., Bandini E., Cenacchi G., Tazzari P.L., Vianelli N., Turroni S., Cavo M., Palandri F., Candela M., and Catani L.

Subjects
Cancer Research, microbial DNA cargo, Microbial DNA, gut microbiota, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Biology, Brief Research Report, medicine.disease, Pathogenesis, Haematopoiesis, Polycythemia vera, medicine.anatomical_structure, Megakaryocyte, polycythemia vera, Oncology, Immunology, medicine, cancer, extracellular vesicle, Myelofibrosis, extracellular vesicles, Dysbiosis, RC254-282, Myeloproliferative neoplasm
Abstract

Polycythemia Vera (PV) is a myeloproliferative neoplasm with increased risk of thrombosis and progression to myelofibrosis. Chronic inflammation is commonly observed in myeloproliferative neoplasms including PV. The inflammatory network includes the extracellular vesicles (EVs), which play a role in cell-cell communication. Recent evidence points to circulating microbial components/microbes as potential players in hemopoiesis regulation. To address the role of EVs in PV, here we investigated phenotype and microbial DNA cargo of circulating EVs through multidimensional analysis. Peripheral blood and feces were collected from PV patients (n=38) and healthy donors (n=30). Circulating megakaryocyte (MK)- and platelet (PLT)-derived EVs were analyzed by flow cytometry. After microbial DNA extraction from feces and isolated EVs, the 16S rDNA V3-V4 region was sequenced. We found that the proportion of circulating MK-derived EVs was significantly decreased in PV patients as compared with the healthy donors. By contrast, the proportion of the PLT-derived EVs was increased. Interestingly, PV was also associated with a microbial DNA signature of the isolated EVs with higher diversity and distinct microbial composition than the healthy counterparts. Of note, increased proportion of isolated lipopolysaccharide-associated EVs has been demonstrated in PV patients. Conversely, the gut microbiome profile failed to identify a distinct layout between PV patients and healthy donors. In conclusion, PV is associated with circulating EVs harbouring abnormal phenotype and dysbiosis signature with a potential role in the (inflammatory) pathogenesis of the disease.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results